NCT03182504View on ClinicalTrials.gov

A Study to Investigate the Intrapulmonary Lung Penetration of Nacubactam in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

June 15, 2017

Primary Completion Date

August 10, 2017

Study Completion Date

August 10, 2017

Conditions
Gram-negative Bacterial Infections
Interventions
DRUG

nacubactam

Participants will receive a single 2000 milligram (mg) intravenous (IV) infusion of nacubactam over 1.5 hours.

DRUG

meropenem

Participants will receive a single 2000 mg IV infusion of meropenem over 1.5 hours.

Trial Locations (1)

85006

Pulmonary Associates Clinical Trials (PACT), Phoenix

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT03182504 - A Study to Investigate the Intrapulmonary Lung Penetration of Nacubactam in Healthy Participants | Biotech Hunter | Biotech Hunter